JP6987859B2 - Ｍａｇｌ阻害剤 - Google Patents

Ｍａｇｌ阻害剤 Download PDF

Info

Publication number
JP6987859B2
JP6987859B2 JP2019523589A JP2019523589A JP6987859B2 JP 6987859 B2 JP6987859 B2 JP 6987859B2 JP 2019523589 A JP2019523589 A JP 2019523589A JP 2019523589 A JP2019523589 A JP 2019523589A JP 6987859 B2 JP6987859 B2 JP 6987859B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019523589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502047A5 (enExample
JP2020502047A (ja
Inventor
エー． グライス，シェリル
ジェイ． バザード，ダニエル
エス． ホワイト，ニコル
エル． ヘルツォーク，ドナルド
Original Assignee
ルンドベック ラ ホーヤ リサーチ センター，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ルンドベック ラ ホーヤ リサーチ センター，インク． filed Critical ルンドベック ラ ホーヤ リサーチ センター，インク．
Publication of JP2020502047A publication Critical patent/JP2020502047A/ja
Publication of JP2020502047A5 publication Critical patent/JP2020502047A5/ja
Application granted granted Critical
Publication of JP6987859B2 publication Critical patent/JP6987859B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019523589A 2016-11-16 2017-11-15 Ｍａｇｌ阻害剤 Expired - Fee Related JP6987859B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423095P 2016-11-16 2016-11-16
US62/423,095 2016-11-16
PCT/US2017/061867 WO2018093946A1 (en) 2016-11-16 2017-11-15 Magl inhibitors

Publications (3)

Publication Number Publication Date
JP2020502047A JP2020502047A (ja) 2020-01-23
JP2020502047A5 JP2020502047A5 (enExample) 2020-12-17
JP6987859B2 true JP6987859B2 (ja) 2022-01-05

Family

ID=62107273

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523589A Expired - Fee Related JP6987859B2 (ja) 2016-11-16 2017-11-15 Ｍａｇｌ阻害剤

Country Status (27)

Country Link
US (1) US9981930B1 (enExample)
EP (1) EP3541822B1 (enExample)
JP (1) JP6987859B2 (enExample)
KR (1) KR20190077087A (enExample)
CN (1) CN110248947B (enExample)
AR (1) AR110088A1 (enExample)
AU (1) AU2017361250A1 (enExample)
BR (1) BR112019009991A2 (enExample)
CA (1) CA3043612A1 (enExample)
CL (1) CL2019001335A1 (enExample)
CO (1) CO2019005038A2 (enExample)
CR (1) CR20190243A (enExample)
DO (1) DOP2019000121A (enExample)
EA (1) EA201991074A1 (enExample)
EC (1) ECSP19035377A (enExample)
ES (1) ES2908632T3 (enExample)
IL (1) IL266550A (enExample)
JO (1) JOP20190105A1 (enExample)
MA (1) MA46860A (enExample)
MX (1) MX2019005771A (enExample)
NI (1) NI201900050A (enExample)
PE (1) PE20191146A1 (enExample)
PH (1) PH12019501102A1 (enExample)
RU (1) RU2019116514A (enExample)
TN (1) TN2019000150A1 (enExample)
TW (1) TW201831458A (enExample)
WO (1) WO2018093946A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2800565T1 (sl) 2012-01-06 2020-10-30 Lundbeck La Jolla Research Center, Inc. Karbamatne spojine in metode izdelave in uporabe le-teh
JP2018515460A (ja) 2015-05-11 2018-06-14 アビデ セラピューティクス，インク． 炎症または神経障害性疼痛を処置する方法
US10899737B2 (en) 2016-09-19 2021-01-26 Lundbeck La Jolla Research Center, Inc. Piperazine carbamates and methods of making and using same
JOP20190106A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
KR102508739B1 (ko) 2016-11-16 2023-03-09 하. 룬드벡 아크티에셀스카브 Magl 억제제의 결정형
PE20200664A1 (es) 2017-08-29 2020-06-11 Lundbeck La Jolla Research Center Inc Compuestos espirociclicos y sus metodos de preparacion y uso
CN111448199A (zh) * 2017-11-02 2020-07-24 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新的高活性的氨基-噻唑取代的吲哚-2-甲酰胺
TW201946906A (zh) 2018-05-15 2019-12-16 美商阿拜德生物製藥公司 Magl抑制劑
US11702393B2 (en) * 2020-04-21 2023-07-18 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
UY39516A (es) 2020-11-13 2022-05-31 H Lundbeck As Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
JP7777891B2 (ja) 2021-12-29 2025-12-01 サイ セラピューティクス インコーポレイテッド モノアシルグリセロールリパーゼ（ｍａｇｌ）の阻害
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (enExample) 1967-10-17 1970-06-01
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
DE69211015T2 (de) 1991-11-27 1997-01-09 Du Pont Herbizide acylierte amino-(phenyl-oder-pyridinyl-oder thienyl-)phenyl derivate
AU1384795A (en) 1993-12-22 1995-07-10 Shell Internationale Research Maatschappij B.V. Process for preparing carbamates
AU7579696A (en) 1995-11-15 1997-06-05 Zeneca Limited Herbicidal substituted pyrazole compounds
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
JP2003511362A (ja) 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー 新規カルバメートおよび尿素類
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
KR20070026382A (ko) 2004-02-18 2007-03-08 아스트라제네카 아베 아세틸린성 피페라진 화합물 및 대사성 글루타메이트수용체 길항제로서 이들의 용도
WO2005100321A1 (en) * 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
CN101087786A (zh) 2004-12-23 2007-12-12 霍夫曼-拉罗奇有限公司 杂环氨基甲酸酯衍生物，它们的制备及作为药剂的应用
DK2937341T3 (en) 2004-12-30 2017-09-11 Janssen Pharmaceutica Nv 4- (BENZYL) -PIPERAZINE-1-CARBOXYLIC ACID PHENYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF FATTY ACID HYDROLASE (FAAH) FOR TREATING ANALYSIS, PAIN AND OTHER CONDITIONS
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
JP2009527459A (ja) 2006-02-23 2009-07-30 武田薬品工業株式会社 縮合窒素含有複素環化合物
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
US7795457B2 (en) 2007-02-26 2010-09-14 Kosan Biosciences Incorporated Carbamate compounds
JP2008239616A (ja) * 2007-02-28 2008-10-09 Iyaku Bunshi Sekkei Kenkyusho:Kk Ｈｄｌ上昇剤
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
US20110118286A1 (en) 2008-07-16 2011-05-19 Santhosh Francis Neelamkavil Bicyclic heterocycle derivatives and their use as gpcr modulators
US8772318B2 (en) 2008-11-14 2014-07-08 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
EP2411010B1 (en) 2009-03-23 2013-11-06 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
RU2570662C9 (ru) 2009-11-03 2016-07-20 Байер Матириальсайенс Аг Фторуретаны в качестве добавки в фотополимерной композиции
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
SI2800565T1 (sl) 2012-01-06 2020-10-30 Lundbeck La Jolla Research Center, Inc. Karbamatne spojine in metode izdelave in uporabe le-teh
CN108912066B (zh) 2012-01-06 2022-06-24 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
MX2014011134A (es) 2012-03-19 2014-12-10 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos.
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
JP6647592B2 (ja) * 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
EP3271352B1 (en) 2015-03-18 2021-05-12 H. Lundbeck A/S Piperazine carbamates and methods of making and using same
JP2018515460A (ja) * 2015-05-11 2018-06-14 アビデ セラピューティクス，インク． 炎症または神経障害性疼痛を処置する方法
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
EP3455226B1 (en) * 2016-05-12 2020-12-30 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190267A1 (ar) * 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl

Also Published As

Publication number Publication date
CR20190243A (es) 2019-06-26
ES2908632T3 (es) 2022-05-03
CO2019005038A2 (es) 2019-05-31
TN2019000150A1 (en) 2020-10-05
RU2019116514A (ru) 2020-12-17
EP3541822A1 (en) 2019-09-25
US9981930B1 (en) 2018-05-29
IL266550A (en) 2019-07-31
AR110088A1 (es) 2019-02-20
MX2019005771A (es) 2019-12-05
ECSP19035377A (es) 2019-05-31
NI201900050A (es) 2019-10-30
BR112019009991A2 (pt) 2019-08-27
JP2020502047A (ja) 2020-01-23
CN110248947A (zh) 2019-09-17
CA3043612A1 (en) 2018-05-24
CN110248947B (zh) 2022-04-01
AU2017361250A1 (en) 2019-05-30
MA46860A (fr) 2019-09-25
EP3541822B1 (en) 2022-01-19
CL2019001335A1 (es) 2019-10-04
DOP2019000121A (es) 2019-09-30
WO2018093946A1 (en) 2018-05-24
KR20190077087A (ko) 2019-07-02
US20180134675A1 (en) 2018-05-17
EA201991074A1 (ru) 2019-12-30
JOP20190105A1 (ar) 2019-05-09
EP3541822A4 (en) 2020-04-29
PH12019501102A1 (en) 2019-08-19
TW201831458A (zh) 2018-09-01
PE20191146A1 (es) 2019-09-02

Similar Documents

Publication Publication Date Title
JP6987859B2 (ja) Ｍａｇｌ阻害剤
JP7042547B2 (ja) Ｍａｇｌ阻害剤
JP7042468B2 (ja) Ｍａｇｌ阻害剤
JP2021523200A (ja) Ｍａｇｌ阻害剤
JP7042804B2 (ja) ピペラジンカルバメート、及びその製造と使用の方法
JP6078601B2 (ja) Ｍｇａｔ２阻害剤としてのアリールジヒドロピリジノンおよびピペリジノン
JP7440572B2 (ja) デュアルｍａｇｌ及びｆａａｈインヒビター
JP2020532547A (ja) スピロ環化合物並びにその作製及び使用方法
JP7282104B2 (ja) Ａｂｈｄ１２阻害剤並びにその製造及び使用方法
HK40009163A (en) Magl inhibitors
HK40009163B (en) Magl inhibitors
NZ753264B2 (en) Magl inhibitors
HK40009161A (en) Magl inhibitors
HK40009161B (en) Magl inhibitors

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20190730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201110

TRDD Decision of grant or rejection written
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211029

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211201

R150 Certificate of patent or registration of utility model

Ref document number: 6987859

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees